Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Neutral Rating from Analysts at Citigroup

Equities researchers at Citigroup began coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report issued on Thursday,Briefing.com Automated Import reports. The firm set a “neutral” rating and a $895.00 price target on the biopharmaceutical company’s stock. Citigroup’s price objective would indicate a potential upside of 11.27% from the stock’s current price.

REGN has been the subject of several other research reports. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,097.14.

Regeneron Pharmaceuticals Price Performance

REGN opened at $804.33 on Thursday. The company has a 50-day moving average of $1,007.57 and a 200-day moving average of $1,037.30. The company has a market capitalization of $88.39 billion, a P/E ratio of 19.90, a PEG ratio of 3.10 and a beta of 0.15. Regeneron Pharmaceuticals has a 1-year low of $784.96 and a 1-year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 7.48% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after purchasing an additional 91,956 shares in the last quarter. Capital International Investors raised its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after purchasing an additional 213,038 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Regeneron Pharmaceuticals by 25.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after acquiring an additional 184,561 shares during the period. International Assets Investment Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after acquiring an additional 11,499 shares during the period. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.